Document Detail

Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
MedLine Citation:
PMID:  19025427     Owner:  NLM     Status:  MEDLINE    
STUDY OBJECTIVE: To assess whether the increased risk of ibutilide-induced torsade de pointes in patients with heart failure may be due to increased ibutilide exposure, we sought to determine if the pharmacokinetics of ibutilide are altered in patients with heart failure due to left ventricular systolic dysfunction. DESIGN: Multicenter, prospective pharmacokinetic study. SETTING: Four academic medical centers in the United States. PATIENTS: Sixteen adult patients with atrial fibrillation or atrial flutter requiring conversion to normal sinus rhythm: six patients who had New York Heart Association (NYHA) class II or III heart failure due to left ventricular dysfunction (mean +/- SD left ventricular ejection fraction [LVEF] 30 +/- 9%); 10 patients who did not have left ventricular dysfunction (mean +/- SD LVEF 54 +/- 5% in six of these 10 patients) served as controls. INTERVENTION: All patients received a single dose of ibutilide 1.0 mg administered intravenously over 10 minutes. Blood samples were obtained through an indwelling catheter in the contralateral arm before ibutilide administration, at the end of the infusion, and at 5, 15, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, and 48 hours after the infusion. MEASUREMENTS AND MAIN RESULTS: Serum ibutilide concentrations were determined by using high-performance liquid chromatography and mass spectrometry. No significant differences were noted between the heart failure and normal left ventricular function groups in the following parameters: maximum serum ibutilide concentration (median [interquartile range] 3.8 [2.3-5.7] vs 5.8 [3.1-14.4] microg/L, p=0.31), area under the serum concentration-time curve from time zero extrapolated to infinity (mean +/- SD 11.0 +/- 9.4 vs 13.2 +/- 10.6 microg*hr/L, p=0.88), steady-state volume of distribution (1380 +/- 334 vs 1390 +/- 964 L, p=0.99), systemic clearance (129 +/- 60 vs 125 +/- 81 L/hr, p=0.92), or half-life (12.5 +/- 10.7 vs 12.4 +/- 8.6 hrs, p=0.99). CONCLUSION: The pharmacokinetics of ibutilide do not appear to be altered in patients with NYHA class II or III heart failure due to left ventricular systolic dysfunction. Therefore, the increased risk of ibutilide-induced torsade de pointes in patients with heart failure does not appear to be due to increased ibutilide exposure.
James E Tisdale; Brian R Overholser; Kevin M Sowinski; Heather A Wroblewski; Kwadwo Amankwa; Steven Borzak; Joanna R Kingery; Rita Coram; Douglas P Zipes; David A Flockhart; Richard J Kovacs
Related Documents :
11927527 - Metoprolol cr/xl in female patients with heart failure: analysis of the experience in m...
6645777 - The search for a digitalis substitute ii milrinone (win 47203). its action on the heart...
8919837 - Rhabdomyolytic acute renal failure in cardiac surgery. a clinical case.
9926117 - Isolated diastolic heart failure--what is it?
18263797 - Growth differentiation factor-15 for prognostic assessment of patients with acute pulmo...
8604627 - Radiofrequency catheter ablation of atrial tachycardias.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacotherapy     Volume:  28     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-11-25     Completed Date:  2009-02-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1461-70     Citation Subset:  IM    
Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Purdue University, 1001 W 10th Street, Indianapolis, IN, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Arrhythmia Agents / adverse effects,  blood,  pharmacokinetics
Area Under Curve
Arrhythmias, Cardiac / chemically induced
Catheters, Indwelling
Electrocardiography / methods
Heart Failure / drug therapy*,  metabolism,  physiopathology
Heart Rate / drug effects
Infusions, Intravenous
Long QT Syndrome / chemically induced
Middle Aged
Monte Carlo Method
Prospective Studies
Remission, Spontaneous
Severity of Illness Index
Sulfonamides / adverse effects,  blood,  pharmacokinetics*
Tachycardia / chemically induced
Time Factors
Ventricular Dysfunction, Left / physiopathology*
Reg. No./Substance:
0/Anti-Arrhythmia Agents; 0/Sulfonamides; 130350-52-6/ibutilide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of opioid requirements and analgesic response in opioid-tolerant versus opioid-naïve pat...
Next Document:  Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin struct...